KZR | tickerfilter.com

Fundamental analysis

31%

Profitability 35%

Dept financing 4%

Liquidity 43%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.70%

1 Month

-6.17%

3 Months

-14.52%

6 Months

966.67%

1 Year

568.45%

2 Year

-8.64%

Key data

Stock price

$6.24

P/E Ratio

0.00

DAY RANGE

$6.16 - $6.47

EPS

-$3.60

52 WEEK RANGE

$0.52 - $8.45

52 WEEK CHANGE

$569.60

MARKET CAP

56.414 M

YIELD

N/A

SHARES OUTSTANDING

72.962 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.46

PUBLIC FLOAT

AVERAGE 10 VOLUME

$20,667

AVERAGE 30 VOLUME

$33,056

Company detail

CEO: John Fowler
Region: US
Website: kezarlifesciences.com
Employees: 60
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.

KZR - Kezar Life Sciences, Inc.